| abstract |
The subject of the invention is a double-stranded oligonucleotide characterized in that it consists of two complementary oligonucleotide sequences forming a hybrid each comprising at one of their 3 'or 5' ends one to five unpaired nucleotides forming single ends. strands bridging the hybrid, one of said oligonucleotide sequences being substantially complementary to a target sequence belonging to a DNA or RNA molecule specifically to be repressed. The invention also relates to the use of said oligonucleotides in pharmaceutical compositions, in particular for the treatment of cancers. |